Ascendis Pharma Oncology Division A/S — Credit Rating and Financial Key Figures
CVR number: 41034076
Tuborg Boulevard 12, 2900 Hellerup
Income statement (kEUR)
2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|
| Fiscal period length | 12 | 12 | 12 | 12 | 12 |
| Net sales | |||||
| Gross profit | -35 705.20 | -46 676.71 | -62 367.39 | - 140 146.00 | -92 475.00 |
| Costs of management | -90.92 | -86.49 | -91.12 | -47.00 | -77.00 |
| EBIT | -35 796.12 | -46 763.20 | -62 458.51 | - 140 193.00 | -92 552.00 |
| Other financial income | 0.00 | 34.74 | 36.33 | 696.00 | 713.00 |
| Other financial expenses | - 347.42 | -1 355.79 | -2 570.16 | -4 842.00 | -14 926.00 |
| Pre-tax profit | -36 143.53 | -48 084.25 | -64 992.34 | - 144 339.00 | - 106 765.00 |
| Income taxes | 63.75 | 104.02 | 80.09 | 229.00 | 390.00 |
| Net earnings | -36 079.78 | -47 980.23 | -64 912.25 | - 144 110.00 | - 106 375.00 |
Assets (kEUR)
2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|
| Intangible rights | 5 265.23 | 2 632.61 | |||
| Intangible assets total | 5 265.23 | 2 632.61 | |||
| Tangible assets total | |||||
| Investments total | |||||
| Long term receivables total | |||||
| Inventories total | |||||
| Current trade debtors | 203.73 | ||||
| Prepayments and accrued income | 135.93 | 41.42 | 15.00 | ||
| Current other receivables | 2 661.05 | 2 484.45 | 5 125.56 | ||
| Short term receivables total | 3 000.71 | 2 525.87 | 5 125.56 | 15.00 | |
| Cash and bank deposits | 203.15 | 449.65 | 478.52 | 442.00 | 99.00 |
| Cash and cash equivalents | 203.15 | 449.65 | 478.52 | 442.00 | 99.00 |
| Balance sheet total (assets) | 8 469.08 | 5 608.14 | 5 604.08 | 457.00 | 99.00 |
Equity and liabilities (kEUR)
2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|
| Share capital | 120.46 | 120.46 | 120.46 | 120.00 | 120.00 |
| Shares repurchased | -64 912.25 | ||||
| Other reserves | 64 912.25 | ||||
| Retained earnings | 7 830.91 | -28 248.88 | -76 229.11 | - 141 141.00 | - 285 251.00 |
| Profit of the financial year | -36 079.78 | -47 980.23 | -64 912.25 | - 144 110.00 | - 106 375.00 |
| Shareholders equity total | -28 128.42 | -76 108.65 | - 141 020.90 | - 285 131.00 | - 391 506.00 |
| Non-current owed to group member | 33 929.33 | 81 709.43 | 146 609.07 | 285 576.00 | 391 591.00 |
| Non-current liabilities total | 33 929.33 | 81 709.43 | 146 609.07 | 285 576.00 | 391 591.00 |
| Current trade creditors | 12.00 | 14.00 | |||
| Short-term deferred tax liabilities | 15.90 | ||||
| Other non-interest bearing current liabilities | 2 305.34 | 7.36 | |||
| Accruals and deferred income | 362.84 | ||||
| Current liabilities total | 2 668.18 | 7.36 | 15.90 | 12.00 | 14.00 |
| Balance sheet total (liabilities) | 8 469.08 | 5 608.14 | 5 604.08 | 457.00 | 99.00 |
Try the full version of our system for free
- Professional credit risk reports
- Create your own estimates for any company
- Valuation analysis
- All 400,000+ Danish companies
- See instructions
... and more!
No registration needed.